By Dr Danielle Meyrick (ITM)2024-06-17T10:00:28
Dr Danielle Meyrick holds a PhD in Physical Chemistry and Radiopharmaceutical Chemistry, and a Doctor of Medicine. Her early career was shaped by various scientific and medical residences at hospitals in the US and Australia. With over 20 years of experience, she is now Chief Medical Officer of ITM and ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-06T09:00:00Z
2026-05-05T13:24:00Z
Sponsored by HUB Organoids
2026-05-01T12:00:00Z
2026-05-05T13:24:00
Sponsored by HUB Organoids
2024-03-08T10:00:25
Sponsored by Molecular Devices
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2024-01-26T13:22:42
Sponsored by bit.bio
2023-07-04T10:05:58
Sponsored by Revvity
2023-01-06T16:37:30
Sponsored by Catalent
Site powered by Webvision Cloud